Item 9 Labs Corp. Announces Reverse Stock Split

SCOTTSDALE, Arizona, October 8, 2018 – Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leading provider of comfortable cannabis health solutions for the modern consumer through the development of innovative products and proprietary delivery platforms, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse split was approved by majority written consent of the Company’s common stockholders and board of directors on October 5, 2018. The reverse split will take effect upon announcement by FINRA, and shares of INLB common stock will trade on a post-split basis under the symbol “INLBD” for a period of 20 business days after effectiveness; thereafter the “D” will be removed and the symbol changed back to INLB.

In addition, the common stock of INLB will trade under a new CUSIP number, with the par value per share remaining at $.0001. A proportionate adjustment will be made to the per-share exercise prices and number of shares issuable under all outstanding stock options and warrants. No fractional shares will be issued in connection with the reverse split. Shareholders with shares held in certificate form will be able to exchange stock certificates by contacting INLB’s transfer agent, Nevada Agency and Transfer Co. Shareholders that hold shares in book-entry form or in brokerage accounts are not required to take any action and will see the impact of the reverse split reflected in their accounts. 

The Company said the reverse split is expected to take the number of outstanding shares from about 1.09 billion to approximately 55 million at the 1-for-20 ratio.

About Item 9 Labs Corp.:

Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. The Company has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 Labs plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.

Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the Company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Investor Relations:
Jeffrey Rassás
(480)463-4246 or 1-833-TOPMEDS (1-833-867-6337)
Email: jeffrey@item9labs.com